Clinical Trial Search

Primary: Frequency of Adverse Events Leading to Discontinuation of Both Telaprevir and Sofosbuvir Among Subjects Treated With Telaprevir and Sofosbuvir — 0 participants

Primary: Overall Survival — 7.3 months

Primary: Phase 1 - Maximum Tolerated Dose (MTD) in Milligrams (mg) — 1600 indoximod dose in mg

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Hyponatremia — 7; 10 participants

Primary: Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group — 41.8; 88.9 mEq/min — p=0.26

Primary: Lung Volume Initiation — 23.3 % Vital Capacity, relative to EEL

Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74

Primary: Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy — 18.69; 20.1 Score

Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants

Primary: Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination — 5; 2; 4; 4 Percentages of Subjects

Primary: Prevention of Venous Thromboembolism (VTE) — 13; 13; 10; 13 percentage of patients with event — p=0.238

Primary: Percentage of Participants With Acute Rejection — 9.1 percentage of participants

Primary: Objective Response Rate — 1; 7; 11 participants

Primary: Number of Participants That Experienced a Dose-limiting Toxicity (DLT) — 3; 0 Participants